Pazopanib halves risk of progression in RCC: Commentary
Publication
, Journal Article
George, DJ
Published in: Oncology Report
September 1, 2009
Duke Scholars
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2009
Issue
FALL
Start / End Page
27
Related Subject Headings
- Oncology & Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
George, D. J. (2009). Pazopanib halves risk of progression in RCC: Commentary. Oncology Report, (FALL), 27.
George, D. J. “Pazopanib halves risk of progression in RCC: Commentary.” Oncology Report, no. FALL (September 1, 2009): 27.
George DJ. Pazopanib halves risk of progression in RCC: Commentary. Oncology Report. 2009 Sep 1;(FALL):27.
George, D. J. “Pazopanib halves risk of progression in RCC: Commentary.” Oncology Report, no. FALL, Sept. 2009, p. 27.
George DJ. Pazopanib halves risk of progression in RCC: Commentary. Oncology Report. 2009 Sep 1;(FALL):27.
Published In
Oncology Report
EISSN
1548-5323
ISSN
1548-5323
Publication Date
September 1, 2009
Issue
FALL
Start / End Page
27
Related Subject Headings
- Oncology & Carcinogenesis